Should I Buy MBOT? MBOT 2026 Analysis

Should You Buy Microbot Medical Inc (MBOT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.860

1 Day change

-2.11%

52 Week Range

4.670

Analysis Updated At

2026/01/26

Microbot Medical Inc (MBOT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising technology and a positive analyst rating, the technical indicators are bearish, financial performance is weak, and there are no significant positive catalysts or trading signals to support immediate investment. A hold stance is recommended until clearer positive trends emerge.

Technical Analysis

The technical indicators for MBOT are bearish. The MACD histogram is negative and expanding, indicating downward momentum. The RSI is neutral at 30.088, and the moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.982), with resistance levels at R1: 2.184 and R2: 2.247.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios suggest bullish sentiment in the options market. However, the implied volatility is high (147.48), indicating significant uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

Analyst Kyle Bauser from Roth Capital has initiated coverage with a Buy rating and a price target of $5.50, citing the technology's potential in complex vascular procedures.

Neutral/Negative Catalysts

EPS dropped significantly by 65% YoY. Additionally, there are no recent news updates, congress trading data, or significant insider or hedge fund activity to support a bullish case.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$3.577 million, which improved by 11.26% YoY. However, EPS dropped by 65% YoY to -0.07. The gross margin remains at 0%. Overall, the financials indicate weak performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Roth Capital analyst Kyle Bauser initiated coverage with a Buy rating and a price target of $5.50, citing the company's innovative technology and its potential to address complex vascular procedures. However, the stock's current price of $2 is significantly below the target, and the full market release of the technology is not expected until April 2026.

2 Analyst Rating

Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 8.75 USD with a low forecast of 5.5 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.900

Low

5.5

Averages

8.75

High

Current: 1.900

Low

5.5

Averages

8.75

High

Roth Capital

Kyle Bauser

Buy

initiated

$5.50

AI Analysis

2025-12-03

Reason

Roth Capital

Kyle Bauser

Price Target

$5.50

AI Analysis

2025-12-03

initiated

Buy

Reason

Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical with a Buy rating and $5.50 price target. The firm says the company's Liberty Endovascular Robotic System achieved FDA clearance in September and has begun commercial use in select U.S. hospitals ahead of a full market release in April 2026. Roth thinks the technology will be useful within procedures that require navigation of complex vascular anatomy while also reducing physical strain and radiation exposure.

H.C. Wainwright

Raghuram Selvaraju

Buy

maintain

$9 -> $12

2025-09-11

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$9 -> $12

2025-09-11

maintain

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Microbot Medical to $12 from $9 and keeps a Buy rating on the shares after the FDA granted 510(k) clearance for the company's Liberty System. This is the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, the analyst tells investors in a research note. The firm says the initial addressable market comprises 2.5M peripheral endovascular procedures annually in the U.S.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MBOT

Unlock Now

MBOT Should I Buy

MBOT Should I Buy

Should You Buy Microbot Medical Inc (MBOT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch